🤫 Unfair Advantage: 10 bargain shares found using this simple toolSee undervalued shares

CRVS shares retains Outperform rating, target steady on potential

EditorNatashya Angelica
Published 19/12/2024, 13:38

CRVS
5.92%

On Thursday, Mizuho (NYSE:MFG) Securities sustained its Outperform rating on shares of Corvus Pharmaceuticals (NASDAQ:CRVS) with a price target of $12.00. The firm's analyst highlighted the first Phase 1 results for soquelitinib in atopic dermatitis (AtD), expressing optimism about the drug's efficacy and safety profile. The analyst noted that the data, which comes from initial dose cohorts, appears competitive compared to existing oral and injected AtD medications.

Despite the promising data, Corvus Pharmaceuticals' stock experienced a significant intra-day drop of 45%, which the Mizuho analyst views as an overreaction. The analyst's confidence is bolstered by positive feedback from key opinion leaders (KOLs) and the belief that soquelitinib already shows better safety and efficacy than current oral AtD drugs, which are associated with safety risks.

The analyst anticipates that upcoming data updates will further clarify soquelitinib's potential. This optimism is reflected in the maintained Outperform rating, suggesting that Mizuho Securities sees a positive trajectory for Corvus Pharmaceuticals' stock based on the drug's development progress.

Corvus Pharmaceuticals is currently engaged in Phase 3 trials for soquelitinib as a treatment for lymphoma, and the Phase 1 data for AtD represents a potential expansion into additional immune disease treatments. The analyst's outlook remains positive, expecting that future data will reinforce the drug's promise in the market.

The maintained $12.00 price target by Mizuho Securities indicates their expectation that Corvus Pharmaceuticals' share value will reach this level, despite the current market reaction. The analyst's comments underscore a belief in the drug's competitive edge and potential for approval and market penetration.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

CRVS: is this perennial leader facing new challenges?

With valuations skyrocketing in 2024, many investors are uneasy putting more money into stocks. Sure, there are always opportunities in the stock market – but finding them feels more difficult now than a year ago. Unsure where to invest next? One of the best ways to discover new high-potential opportunities is to look at the top performing portfolios this year. ProPicks AI offers 6 model portfolios from Investing.com which identify the best stocks for investors to buy right now. For example, ProPicks AI found 9 overlooked stocks that jumped over 25% this year alone. The new stocks that made the monthly cut could yield enormous returns in the coming years. Is CRVS one of them?

Unlock ProPicks AI to find out

Latest comments

Loading next article…
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.